The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study

• Published in: Gastroenterology research and practice 2020, Vol.2020, p.9656040-7
• Main Authors: Tomie, Akira, Yoshida, Naohisa, Kugai, Munehiro, Hirose, Ryohei, Dohi, Osamu, Inoue, Ken, Okuda, Kotaro, Motoyoshi, Takayuki, Fukumoto, Kohei, Inagaki, Yoshikazu, Yoriki, Hiroyuki, Inada, Yutaka, Okuda, Takashi, Hasegawa, Daisuke, Ogiso, Kiyoshi, Murakami, Takaaki, Soga, Koichi, Rani, Rafiz Abdul, Yoshida, Norimasa, Itoh, Yoshito
• Format: Article
• Language: English
• Subjects: Acids; Age; Antacids; Antidepressants; Bile; Care and treatment; Cohort analysis; Constipation; Deoxycholic acid; Diabetes; Disease; Drug dosages; Females; Gender; Hospitals; Hypothyroidism; Laxatives; Linaclotide; Lubiprostone; Medical research; Medicine, Experimental
• ISSN: 1687-6121; 1687-630X
• DOI: 10.1155/2020/9656040

Backgrounds and Aims. Elobixibat is a bile acid transporter inhibitor indicated for constipation. Previous studies were performed mainly for the nonelderly and were biased to female. We analyzed the efficacy of elobixibat also for the elderly and male. Materials and Methods. This was a multicenter retrospective cohort study. The subjects were patients aged ≥20 years treated for chronic constipation from May 2018 to November 2019 at 12 related institutions. Patients were divided into ≤74 years and ≥75 years old. Elobixibat at 10 mg/day was prescribed for two weeks. We then analyzed the discontinuation due to ineffectiveness, change of spontaneous bowel movements (SBM), stool consistency, the time until the first SBM, adverse events, and effect-related factors. Results. There were 140 cases (61 males) evaluated, with an average age of 72.1±13.6 years (≤74 years: 71 cases; ≥75 years: 69 cases). The discontinuation rate was 7.9%. The SBM (times/week) increased from 2.86 to 6.08 (p